Overview Financials News + Filings Key Docs Ownership Insiders
|
Zymeworks Inc.
| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/30/2023 | Campoy Carlos | Director | Grant | Stock Option (Right to Buy) | 50k | $8.64 | $432k | | 06/30/2023 |
| 03/10/2023 | Klompas Neil A | President & COO | Exercise | Restricted Stock Unit | 2.7k | $0.00 | $0 | | 03/10/2023 |
| 03/10/2023 | Klompas Neil A | President & COO | Sale | Common Stock | 3k | $7.83 | $23.3k | | 03/10/2023 |
| 03/10/2023 | Klompas Neil A | President & COO | Exercise | Restricted Stock Unit | 2.5k | $0.00 | $0 | | 03/10/2023 |
| 01/20/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 163.4k | $9.88 | $1.6M | See Note 1 | 01/19/2023 |
| 01/19/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 144.1k | $9.49 | $1.4M | See Note 1 | 01/19/2023 |
| 01/18/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 203k | $10.00 | $2M | See Note 1 | 01/13/2023 |
| 01/17/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 440k | $9.80 | $4.3M | See Note 1 | 01/13/2023 |
| 01/13/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 342.1k | $9.81 | $3.4M | See Note 1 | 01/13/2023 |
| 01/11/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 106.3k | $7.87 | $836.9k | See Note 1 | 01/10/2023 |
| 01/10/2023 | EcoR1 Capital, LLC | 10% Owner | Purchase | Common Stock | 920k | $7.65 | $7M | See Note 1 | 01/10/2023 |
| 01/05/2023 | Moore Paul Andrew | Chief Scientific Officer | Grant | Restricted Stock Unit | 51.5k | $0.00 | $0 | | 01/05/2023 |
| 01/05/2023 | Moore Paul Andrew | Chief Scientific Officer | Grant | Stock Option (Right to Buy) | 77.5k | $8.00 | $620k | | 01/05/2023 |
| 01/05/2023 | Klompas Neil A | President & COO | Grant | Restricted Stock Unit | 58.5k | $0.00 | $0 | | 01/05/2023 |
| 01/05/2023 | Klompas Neil A | President & COO | Grant | Stock Option (Right to Buy) | 87.5k | $8.00 | $700k | | 01/05/2023 |
| 01/05/2023 | Galbraith Kenneth | Chair & CEO | Grant | Stock Option (Right to Buy) | 215k | $8.00 | $1.7M | | 01/05/2023 |
| 01/05/2023 | Galbraith Kenneth | Chair & CEO | Grant | Restricted Stock Unit | 143k | $0.00 | $0 | | 01/05/2023 |
| 01/05/2023 | Astle Christopher | SVP & CFO | Grant | Restricted Stock Unit | 31.5k | $0.00 | $0 | | 01/05/2023 |
| 01/05/2023 | Astle Christopher | SVP & CFO | Grant | Stock Option (Right to Buy) | 47k | $8.00 | $376k | | 01/05/2023 |
| 12/12/2022 | Astle Christopher | SVP & CFO | Sale | Common Stock | 887 | $6.01 | $5.3k | | 12/12/2022 |
| 12/12/2022 | Astle Christopher | SVP & CFO | Exercise | Restricted Stock Unit | 1.6k | $0.00 | $0 | | 12/12/2022 |
| 11/10/2022 | Josephson Neil | Chief Medical Officer | Sale | Common Stock | 2.5k | $8.10 | $20k | | 11/10/2022 |
| 11/10/2022 | Josephson Neil | Chief Medical Officer | Exercise | Restricted Stock Unit | 5.9k | $0.00 | $0 | | 11/10/2022 |
| 10/13/2022 | Redmile Group, LLC | 10% Owner | Grant | Common Stock, par value $0.00001 per share | 30.5k | $5.03 | $153.4k | See Footnote | 10/13/2022 |
| 10/13/2022 | Redmile Group, LLC | 10% Owner | Purchase | Common Stock, par value $0.00001 per share | 30.5k | $5.03 | $153.4k | See Footnote | 10/13/2022 |
|